IN BRIEF: RTW Biotech invests in inflammation treatment firm Evommune
RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in the life sciences sector - Makes an investment in new portfolio company Evommune Inc, a biotechnology company developing therapies for chronic inflammatory disease, as part of a Series C funding round. The company received a legacy position in Evommune earlier this year after its acquisition of Arix Bioscience and its assets. Read More